Lacourcière Yves, Poirier Luc, Lefebvre Jean
Hypertension Research Unit, Centre Hospitalier de l'Université Laval, Sainte-Foy, Quebec, Canada.
Can J Cardiol. 2007 Apr;23(5):377-82. doi: 10.1016/s0828-282x(07)70771-7.
The present study investigated whether initiating therapy with a combination of losartan (L) and hydrochlorothiazide (HCTZ) allows for faster blood pressure (BP) control and fewer medications than the usual stepped-care approach in patients with stage 2 or 3 hypertension and ambulatory systolic hypertension.
Patients with a mean daytime systolic ambulatory BP (ABP) of 135 mmHg or higher were randomly assigned to receive L 50 mg plus HCTZ 12.5 mg titrated to L 100 mg plus HCTZ 25 mg versus HCTZ 12.5 mg plus atenolol 50 mg. Amlodipine 5 mg was then added, if needed, to achieve a BP goal of less than 130 mmHg. Treatment titration was based on ABP.
Significantly more patients randomly assigned to L/HCTZ (63.5%) than stepped-care (37.5%; P=0.008) achieved the primary end point (daytime systolic BP of less than 130 mmHg). Initial L/HCTZ induced significantly greater decreases in ABP during each 24 h period after six weeks of therapy. Although reductions in systolic and diastolic ABP were not statistically different at the end of the study, ABP reduction was significantly greater (P<0.001) with the L/HCTZ-based regimen. Twice as many patients in the L/HCTZ group achieved the goal ABP with no more than two drugs (30.0% versus 14.7%; P=0.03). Moreover, tolerability was significantly better (P=0.006) in the L/HCTZ group, with a 40.0% incidence of adverse events, versus 65.6% in the stepped-care group.
Initiating antihypertensive therapy with the combination of L/HCTZ in patients with stage 2 or 3 hypertension and ambulatory systolic hypertension reaches a target BP faster in a higher proportion of patients, with fewer adverse events and less need for a third drug regimen than the conventional stepped-care approach.
本研究调查了对于2期或3期高血压及动态收缩期高血压患者,与常规阶梯式治疗方法相比,起始使用氯沙坦(L)和氢氯噻嗪(HCTZ)联合治疗是否能更快控制血压(BP)且用药更少。
平均日间动态收缩压(ABP)为135 mmHg或更高的患者被随机分配接受L 50 mg加HCTZ 12.5 mg并滴定至L 100 mg加HCTZ 25 mg,与HCTZ 12.5 mg加阿替洛尔50 mg进行对比。如有需要,随后添加氨氯地平5 mg以实现血压目标低于130 mmHg。治疗滴定基于ABP。
随机分配至L/HCTZ组的患者(63.5%)显著多于阶梯式治疗组(37.5%;P = 0.008)达到主要终点(日间收缩压低于130 mmHg)。在治疗六周后的每个24小时期间,初始L/HCTZ导致ABP显著更大幅度的下降。尽管在研究结束时收缩压和舒张压ABP的降低无统计学差异,但基于L/HCTZ的治疗方案ABP降低幅度显著更大(P < 0.001)。L/HCTZ组中达到目标ABP且用药不超过两种的患者数量是另一组的两倍(30.0%对14.7%;P = 0.03)。此外,L/HCTZ组的耐受性显著更好(P = 0.006),不良事件发生率为40.0%,而阶梯式治疗组为65.6%。
对于2期或3期高血压及动态收缩期高血压患者,起始使用L/HCTZ联合进行抗高血压治疗,与传统阶梯式治疗方法相比,能使更高比例的患者更快达到目标血压,不良事件更少,且对第三种药物治疗方案的需求更少。